SBRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This study is an open-label, single-arm phase 2 trial to evaluate the efficacy and safety of
stereotactic body radiotherapy (SBRT) for patients with residual oligometastases of NSCLC
after 3rd generation EGFR-TKIs.